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Glycosylphosphatidylinositol (GPI), a glycolipid that 
is ubiquitously present in eukaryotic cells, has been im-
plicated in the pathogenesis of many parasitic diseases 
(Debierre-Grockiego 2010). In malaria, the GPI struc-
tures of Plasmodium falciparum are conserved among 
isolates (Berhe et al. 1999). This molecule is released 
at the end of the schizogonic process and induces an 
important host immune response, which includes the 
production of pro-inflammatory cytokines, such as tu-
mour necrosis factor-α, interleukin (IL)-1 and IL-6 and 
the augmented expression of cell adhesion molecules on 
macrophages and vascular endothelial cells (Schofield 
et al. 1996). The clinical presentation of the toxaemic 
syndrome that accompanies the septicaemia caused by 
Gram-negative bacteria (van Amersfoort et al. 2003) and 
the usual triad of clinical symptoms of malaria (fever, 
chills and sweating, which are commonly accompanied 
by headache) are similar and can result from the pro-
inflammatory responses that are induced by lipopoly-
saccharide and P. falciparum GPI, respectively. These 
pro-inflammatory responses can also account for the de-
velopment of complications, such as severe anaemia and 
the cerebral form of malaria. Indeed, the administration 
of P. falciparum GPI in mice induces malaria-like symp-
toms (Schofield et al. 1993) and immunisation with a 
non-toxic moiety of GPI that elicits an anti-GPI antibody 
(Ab) response can prevent malaria pathology and death 
caused by experimental Plasmodium berghei ANKA 
[because of the discovery of this murine African Plas-
modium in Katanga (NK for New York-Katanga) and in 
Kasapa (ANKA for Antwerpen-Kasapa (Vincke & Ba-
fort 1968)] infection in mice (Schofield et al. 2002).
Studies performed in areas of high malaria transmis-
sion in Africa and Indonesia have demonstrated the po-
tential protective role of the anti-GPI response in malaria 
(Naik et al. 2000) and the association of the anti-GPI re-
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Anti-glycosylphosphatidylinositol (GPI) antibodies (Abs) may reflect and mediate, at least partially, anti-disease 
immunity in malaria by neutralising the toxic effect of parasitic GPI. Thus, we assessed the anti-GPI Ab response in 
asymptomatic individuals living in an area of the Brazilian Amazon that has a high level of malaria transmission. 
For comparative purposes, we also investigated the Ab response to a crude extract prepared from Plasmodium fal-
ciparum, the merozoite surface protein (MSP)3 antigen of P. falciparum and the MSP 1 antigen of Plasmodium vivax 
(PvMSP1-19) in these individuals and in Angolan patients with acute malaria. Our data suggest that the Ab response 
against P. falciparum GPI is not associated with P. falciparum asymptomatic infection in individuals who have been 
chronically exposed to malaria in the Brazilian Amazon. However, this Ab response could be related to ongoing para-
sitaemia (as was previously shown) in the Angolan patients. In addition, our data show that PvMSP1-19 may be a good 
marker antigen to reflect previous exposure to Plasmodium in areas that have a high transmission rate of P. vivax.
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sponse with age (Naik et al. 2000, Keenihan et al. 2003). 
According to these studies, anti-GPI Ab would reflect 
and mediate, at least partially, anti-disease immunity in 
malaria by neutralising the toxic effect of parasitic GPI 
(de Souza et al. 2010). However, studies by Boutlis et 
al. (2002) and Cissoko et al. (2006) found no relation-
ship between anti-GPI Ab levels and clinical protection 
from the disease. Here, we investigate the anti-GPI Ab 
response in asymptomatic individuals living in Barce-
los, an area of the Brazilian Amazon with high endemic 
levels of malaria. Twenty-eight asymptomatic individu-
als ranging from three-50 years of age (mean = 22) with 
either P. falciparum (n = 13) or Plasmodium vivax (n = 
15) infections and 12 non-infected individuals ranging 
from three-66 years of age (mean = 16) with no declared 
previous history of malaria were recruited in Barcelos, 
which has an annual parasitic index (API) of 70.9 cases 
of malaria per 1,000 inhabitants. In a fieldwork conduct-
ed from 2004-2007 (Suárez-Mutis 2007), these asymp-
tomatic individuals tested positive for the presence of P. 
falciparum and P. vivax DNA by polymerase chain reac-
tion (PCR) (Snounou 1996). None of these asymptomatic 
individuals were positive when tested by microscopic 
examination at the time of blood collection or presented 
any symptoms during the 30 days preceding or the 30 
days succeeding the PCR diagnosis; none of these in-
dividuals received anti-malarial treatment during this 
timeframe. All individuals reported previous malaria 
attacks (3-12; mean = 7.3) from both P. falciparum and 
P. vivax. Comparatively, we also studied 97 individuals 
ranging from 15-67 years of age (mean = 26) with non-
complicated P. falciparum malaria that was diagnosed 
by microscopic examination (parasitaemia ranging from 
500-3,000; mean = 1,320 parasites/µL). These individu-
als lived in Lubango, which is an area of intense malaria 
transmission in Angola (API = higher than 100 cases per 
1,000 inhabitants, depending on the season) and were 
diagnosed and treated at the Central Lubango Hospital. 
Brazilian individuals living in the non-endemic south-
east region that had never visited malaria-endemic areas 
were included in the study to establish a threshold (or 
cut-off) value for ELISA detection. The statistical analy-
sis was performed using Epi Info® software v. 7 (Centers 
for Disease Control and Prevention). This study was ap-
proved by Brazilian (Fiocruz, state of Rio de Janeiro, 
CEP157/02) and Angolan Ethical Committees (National 
Malaria Control Program).
The presence of anti-GPI Ab in plasma samples was 
detected by ELISA (Naik et al. 2000) using P. falcipa- 
rum GPI extracted from in vitro culture; the extraction 
of GPI was done according to the method described 
by Berhe et al. (1999) that maintains the GPI structure 
required for the recognition of the native molecule. 
Briefly, because late trophozoites (30-40 h) have been 
shown to have the largest GPI pool (Schmidt et al. 1998), 
GPI was extracted from 1 x 109 trophozoites in a one-
step process that allowed the simultaneous extraction 
of all GPI intermediates and free GPI anchors. A mix-
ture of chloroform:methanol (1:1, v:v) was added to the 
sediment so that the final proportion of solvents (which 
comprised the aqueous phase of the crude parasite GPI 
extract) was 10:10:3 (v:v:v) chloroform:methanol:water 
(C:M:W). The suspension was sonicated for 5 min and 
then centrifuged (18,000 g at 25ºC for 5 min). The super-
natant was collected and the sediment was subsequently 
extracted two more times with 1 mL C:M:W (10:10:3, 
v:v:v). All of the supernatants were pooled and dried in 
a SpeedVac vacuum evaporator to obtain C:M:W eryth-
rocytic extracts. To remove water-soluble contaminants, 
such as nucleotides and phosphate sugars and other lip-
ids, such as phospho and sphingolipids, “Folch washing” 
was performed (Folch et al. 1957, Field & Menon 1992). 
The lipid extract was then resuspended in 1:1 (v:v) C:M 
and 1/5 volume of 4 mM MgCl2 was added. The suspen-
sion was mixed and centrifuged (18,000 g at 25ºC for 
5 min). The upper phase was removed and the organic 
phase was washed twice with 1/2 volume of an artificial 
upper phase (C:M:W:1 M MgCl2, 6:96:94:0.336, v:v:v:v). 
The C:M extracts were vacuum-dried and submitted to 
a butanol:water phase partition. The dried C:M extracts 
were resuspended in 200 µL water-saturated n-butanol 
and then the same volume of water was added. After 
mixing, the extracts were centrifuged (18,000 g at 25ºC 
for 5 min) and the aqueous phase was removed. This 
process was repeated twice. The aqueous phases were 
then pooled and back-washed with 200 µL water-satu-
rated n-butanol. Finally, the butanol phases were pooled, 
yielding the entire P. falciparum GPI content (Gerold et 
al. 1994), which was used as an antigen in this study.
Ideally, after the collection of the butanol phases, the 
GPI extraction is followed by an additional purification 
step using metabolic [3H] glucosamine to label the GPI for 
high-performance liquid chromatography. However, [3H] 
glucosamine was not available at our institution due to 
environmental restrictions. [3H] glucosamine has a half-
life of approximately 13 years and is potentially harmful 
to health and the environment. Because GPIs are, so far, 
the only known glycoconjugates present in P. falciparum 
parasites (Gerold et al. 1994, Schmidt et al. 1998, Berhe 
et al. 1999, Azzouz et al. 2008) and because the solvent 
specificity for GPI extraction (C:M:W) together with the 
subsequent washing step assured the elimination of even-
tual contaminants (Folch et al. 1957, Field & Menon 1992), 
we decided to use the P. falciparum GPI pool without an 
additional radioactivity purification step. To circumvent 
false-positive ELISA results, additional “GPI controls”, 
obtained from non-parasitised erythrocytes (treated or 
not with saponin and submitted to the same extraction 
protocol), were utilised; only one saponin-treated and two 
non-saponin-treated non-parasitised erythrocyte samples 
out of 137 were found to be positive.
There are no reports of P. vivax GPI extraction and 
asymptomatic P. vivax-infected individuals were also 
tested for P. falciparum GPI because they had previous 
P. falciparum infections. ELISA positivity was calcu-
lated using the index of reactivity (IR) ratio (the absor-
bance value of each sample divided by the cut-off value; 
the samples with a ratio of ≥ 1 were considered positive). 
The cut-off value for each reaction was calculated as the 
mean plus two times the standard deviation of a sera 
panel from 20 clinically healthy individuals who neither 
lived in nor visited malaria-endemic areas.
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The frequency and reactivity of anti-GPI Ab in indi-
viduals from Barcelos with asymptomatic P. falciparum 
infection were not significantly different (p > 0.05) from 
those recorded in non-infected individuals from the 
same area without a previous history of malaria (Fig-
ure, Table). The same was true for P. vivax asymptom-
atic carriers. Because GPI levels decline with time after 
infection, we divided the individuals from Barcelos into 
three groups according to the time elapsed after their last 
malaria attack caused by P. falciparum infection (≤ 2 
months, > 2 and ≤ 6 months and > 6 and ≤ 12 months) (n 
= 28). The anti-GPI Ab levels in these three groups were 
then analysed. Anti-GPI Ab levels ranged from 1.01-
1.42 IR (mean = 1.2) and were independent of the time 
of infection. Therefore, this parameter does not seem to 
be relevant in determining the anti-GPI Ab level. Con-
versely, patients from Lubango with P. falciparum ma-
laria had a significantly higher anti-GPI Ab frequency 
(p < 0.0001, analysis of variance) and reactivity (p < 
0.0001, Student’s t test) (Figure, Table). These contrast-
ing data do not support the hypothesis that the anti-GPI 
Ab level reflects clinical immunity to malaria (Naik et 
al. 2000, de Souza et al. 2002, Keenihan et al. 2003), but 
are in accordance with the conclusions of Boutlis et al. 
(2002) and Cissoko et al. (2006). Although the anti-GPI 
response was not higher in asymptomatic infection, this 
response seemed to be related to age; positive individu-
als were older (33.8 ± 7.2) than negative individuals (18.6 
± 14.5) (p < 0.03, Student’s t test), indicating a possible 
association with repeated and chronic infection, which 
accompany aging in endemic areas. Indeed, the anti-GPI 
response tended to correlate with the number of past epi-
sodes of malaria, even though this correlation did not 
reach statistical significance; positive individuals had 
more previous malaria attacks (8.8 ± 2.7) than the nega-
tive individuals (6.0 ± 3.2) (p < 0.08, Student’s t test). 
Moreover, it has already been reported that the preva-
lence and concentration of anti-GPI Ab in hyperendemic 
areas of malaria increase with age (Naik et al. 2000, 
Boutlis et al. 2002, de Souza et al. 2002). Conversely, in 
the symptomatic malaria patients from Lubango, the GPI 
immune response was independent of age, but was posi-
tively correlated with parasitaemia (r = 0.398; p = 0.010, 
Spearman’s rank correlation), which could have resulted 
from a booster effect of parasitic antigens during acute 
infection. Similar observations have been described by 
de Souza et al. (2002) and Cissoko et al. (2006), who 
reported that in cases of clinical malaria, anti-GPI Ab 
can be augmented in a parasitaemia-dependent manner. 
Considering our results here, we hypothesise that in the 
patients with uncomplicated malaria from Lubango, GPI 
Abs could protect against the development of severe ma-
laria because circulating anti-GPI Abs can neutralise the 
toxic effects of parasitic GPI (Naik et al. 2000).
To further characterise the previous exposure of the 
studied individuals to Plasmodium, we also evaluated the 
Ab response to a crude P. falciparum extract by ELISA 
[obtained according to Sanchez et al. (1993)] as well as 
to the recombinant merozoite surface proteins (MSP) of 
P. falciparum (Pf MSP3) (a kind gift from Pierre Druilhe 
from Vac-4-All) and P. vivax (PvMSP1-19) (produced by 
Arianni Rondelli Sanchez and Eduardo Milton Ramos-
Sanchez at the Institute of Tropical Medicine, state of 
São Paulo, Brazil), as described elsewhere (Theisen et 
al. 2001, Cunha et al. 2001, respectively). The Ab lev-
els to all antigens in the asymptomatic individuals were 
TABLE
Frequency of antibodies (Abs) detected by ELISA against glycosylphosphatidylinositol (GPI), the crude extract (PfAg)  
and the recombinant protein merozoite surface proteins (MSP) of Plasmodium falciparum (Pf MSP3)  
and the recombinant protein of Plasmodium vivax (PvMSP1-19)
Groups
Frequency of Abs
(%)
GPI PfAg Pf MSP3 PvMSP1-19
Asymptomatics (Barcelos) 18 96 46 86
Non-infected controls (Barcelos) 42 50 42 17
Malaria patients (Lubango) 65 70 44 2
Antibody (Ab) reactivity against Plasmodium falciparum glycosyl-
phosphatidylinositol (GPI) in serum samples from asymptomatic P. 
falciparum (aPf) and Plasmodium vivax (aPv) infected and control 
(C) individuals from Barcelos (Brazilian Amazon), as well as from 
malarious P. falciparum (mPf) patients from Lubango (Angola). Sam-
ples were diluted at 1:100 and the Ab reactivity to P. falciparum GPI 
(IgG) was detected by ELISA. Individuals never exposed (NE) to ma-
laria were used as negative controls.
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significantly related to age (crude antigen: r = 0.523, p = 
0.004; Pf MSP3: r = 0.386, p = 0.04 and PvMSP1-19: r = 
0.496, p = 0.007, Spearman’s rank correlation), indicat-
ing that, in a scenario of supposed premunition to ma-
laria in areas of intense disease transmission (including 
those in the Brazilian Amazon), antiparasitic responses 
can be associated with age and the consequent cumula-
tive exposure to infection. This idea has been classically 
reported for the hyperendemic areas of Africa (Soe et al. 
2001, Dodoo et al. 2008). In Brazilian endemic areas, it 
has also been shown that the Ab response to PvMSP1-19 
increases with age and/or time of exposure to malaria 
(Braga et al. 2002, Nogueira et al. 2006). Additionally, 
the Ab response has even been linked to the absence of 
clinical symptoms (Nogueira et al. 2006). However, in 
the African patients with acute P. falciparum malaria, 
the Abs against the P. falciparum extract and Pf MSP3 
were associated with parasitaemia, supporting our data 
obtained for GPI that suggest a rather non-protective im-
mune response linked to acute infection.
An interesting issue raised in our study was the ob-
servation of a high prevalence of Ab to P. falciparum 
blood-stage antigens, including PfMSP3, among the con-
trol individuals from Barcelos (Table). This was the first 
time it was studied in a Brazilian endemic area. These 
individuals presenting Ab to MSP3, but not Ab to GPI 
never reported previous malaria episodes nor were found 
to be infected with plasmodia by PCR analysis. The simi-
lar positivity of anti-PfMSP3 Ab in both Brazilians who 
had been exposed to infection, but did not have a previ-
ous history of malaria infection and Angolans who pre-
sented with malaria with positive thick blood smears is 
quite surprising and could be explained in a number of 
ways: (i) the Brazilian individuals could have had atypi-
cal malaria attacks that were not recognised as classical 
manifestations of the disease, (ii) PfMSP3 could have 
cross-reacted with molecules from other microorganisms 
that are present in the region or (iii) the anti-PfMSP3 Ab 
response might not have accurately reflected earlier ex-
posure of the African individuals to the parasite.
In this study, the anti-PvMSP1-19 Ab response seems 
to adequately reflect previous experience with P. vivax. 
These observations are in agreement with a study con-
ducted in another malarious Brazilian region (Cotijuba, 
Belém, state of Pará) with exclusive transmission of P. 
vivax, in which 50% of individuals with no past history 
of the disease presented Abs against the blood stages of 
P. vivax, as measured by indirect fluorescent antibody 
test, while only approximately 6% of these individuals 
presented Abs against PvMSP1-19, as measured by ELISA 
(Soares et al. 1999). In addition to the low prevalence of 
anti-PvMSP1-19 Ab (17%) recorded in the control subjects 
from Barcelos, we observed a very low prevalence (2%) 
of these Abs among African patients living in areas where 
P. falciparum is highly prevalent. In contrast, these Abs 
were present in 86% of the asymptomatic infected sub-
jects from Barcelos, where P. vivax is the major malaria-
causing species. These data suggest that the assessment of 
positivity to Abs reacting with PvMSP1-19 could be valu-
able to define exposure to P. vivax in endemic areas.
In summary, the data presented here, which for the 
first time address the anti-P. falciparum GPI immune 
response in Brazil, indicate that the Ab response against 
P. falciparum GPI is not associated with asymptomatic 
infection in individuals who have been chronically ex-
posed to malaria in the Brazilian Amazon. These data 
are in agreement with data from other African endemic 
areas (de Souza et al. 2002, Cissoko et al. 2006). Supple-
mentary studies with a higher number of asymptomatic 
individuals comparatively to patients with acute malaria 
from the same origin will increase the understanding of 
the relationship between anti-GPI Ab responses and as-
ymptomatic infection.
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